MS Xevo G2 Q-Tof ESI+ 1 2 / pm-4 00 am 2 00 am # am # am #3 / pm am am #4 0.8 kv 20 V MS E ev MS E MASSLYNX
|
|
|
- まれあ いそみ
- 7 years ago
- Views:
Transcription
1 UPLC-Tof-MS E John Archer, 1 Paul Dargan, 1 David Wood, 1 Nayan Mistry, 2 and Michelle Wood 2 1 Guy s and St. Thomas NHS Foundation Trust, Clinical Toxicology, London, UK 2 Waters Corporation, MS Technologies Centre, Manchester, UK British Crime Survey 2010/ Dance magazine Mixmag MDMAcocaine mephedrone mephedrone UPLC /Tof-MS E UPLC/Tof-MS E ACQUITY UPLC Xevo G2 Q-Tof TM ACQUITY UPLC HSS C18 Tof UPLC-Tof-MS E 1
2 MS Xevo G2 Q-Tof ESI+ 1 2 / pm-4 00 am 2 00 am # am # am #3 / pm am am #4 0.8 kv 20 V MS E ev MS E MASSLYNX Targetlynx TM ChromaLynx TM Posi ive TM 5 UPLC ACQUITY UPLC ACQUITY UPLC HSS C x 150 mm 1.8 µm µl A B 5 mm (ph 3.0) 0.1% A B 400 µl/min 15 UPLC-Tof-MS E 2
3 A Waters Xevo G2 Q-Tof MS E RT B Potential adulterants C 1 MS E A-C 4-fluoroamphetamine(4-FA) MS E - 2 A T-Wave TM B C UPLC-Tof-MS E 3
4 4 1 Amphetamine + Cocaine + Ketamine + Methamphetamine Morphine MDMA + Mephedrone (4-MMC) + NRG-2 (4-MEC) 2-AI TFMPP Diltiazem levamisole caffeine lidocaine quinine Potential adulterants OTC 2 #2 MS E Mephedrone (4-methylmethcathinone) amphetamine (MDMA MDA methamphetamine) cocaine ketamine paracetamol levamisole atazanavir nevirapine UPLC-Tof-MS E 4
5 Xevo G2 Q-Tof Smith K, Flatley J. Drug misuse declared: findings from the 2010/2011 British Crime Survey. HOSB (2011). science-research-statistics/research-statistics/home-office-science/ consult-drug-misuse-12?view=standard&pubid= (last accessed 25th May 2012). 2. Winstock A. Drugs survey. Mixmag. 2011; 238: Archer JRH, Dargan PL, Hudson S, Davies S, Puchnarewicz M, Kicman AT, Ramsey J, Measham F, Wood M, Johnston A, Wood DM. Taking the pissoir-a novel way of knowing what drugs are being used in the nightclubs. Submitted to Journal of Substance Abuse TEL FAX F TEL FAX Waters ACQUITY UPLC Xevo UPLC MassLynx Waters Corporation Q-Tof T-Wave TargetLynx ChromaLynx Posi ive The Science of What s Possible Waters Corporation 2013 Waters Corporation. Printed in Japan JA PDF
Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPL
ACQUITY UPLC I-Class/Xevo TQD Mark Roberts and Michelle Wood Waters Corporation, MS Technologies Centre, Manchester, UK ACQUITY UPLC I-Class/Xevo TQD 2 2 MRM 178 / 950 MS ACQUITY UPLC/ACQUITY TQD 2 1-3
LC LC ACQUITY UPLC H-Class ACQUITY UPLC CSH C mm 1.7 µm : THF/ 2/8 A 1 mm / 4/6 THF 2 mg/ml THF/ 2 THF 2 ACQUITY UPLC CSH C 18
ACQUITY UPLC H-Class/QDa Nihon Waters K.K., Tokyo, Japan TAG 1 3 1 1 8 9 TAG TAG TAG TAG TAG UV UV APCI ESI MS TAG Sn-2 Sn-3 Sn-1 C18: ACQUITY UPLC CSH C 18 ACQUITY UPLC H-Class 1. ACQUITY QDa TAG ACQUITY
HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HIL
HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HILIC UPLC HPLC 1 100 µl 900 µl 15 900 µl 500 µl 470 µl
ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB 3.
UPC 2 Andrew Aubin Waters Corporation, Milford, MA, USA Waters ACQUITY UPC 2TM 6 tert- UltraPerformance Convergence Chromatography TM UPC 2 ACQUITY UPC 2 1 A A D3 E D3 K1 K2 UPC 2 A E K1 ACQUITY UPC 2
1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C).91 177 2 Thiamine (B1) 1.1 265 5 Nicotinic Acid (B3) 1.27 124 15 Pyridoxal (
ACQUITY UPLC H-Class ACQUITY QDa Mark E. Benvenuti, Dimple Shah, and Jennifer A. Burgess Waters Corporation, Milford, MA, USA MS ACQUITY QDa UPLC HPLC UV ACQUITY QDa LC EC 1925/26 CFR 21 HPLC 1 LC-MS ACQUITY
UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC
UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC 2 1-3 GC LC GC UltraPerformance Convergence Chromatography
[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2
![[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2](/thumbs/91/106196485.jpg "[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2")
N [ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2 [ GLYC AN ANALYSIS SLUTINS ] インタクトプロテイン解析のワークフロー 糖タンパク質 Intact mab Mass Check スタンダード LC 分析カラムにインジェクション UV 検出による
2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP
2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP DNA 1 100 ppm HCPHCP HCP HCP 2008 EMA HCP 1 2006 HCP
LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY
Ultra Performance Liquid Chromatography Stephan Koza, Paula Hong, and Kenneth J. Fountain Waters Corporation, 34 Maple Street, Milford, MA, USA & SEC 2010 2 8 5 2030 4 3 8 1982 2009 131 USP EPHMW USP34
:010_ :3/24/2005 3:27 PM :05/03/28 14:39
:010_896300101703 :3/24/2005 3:27 PM :05/03/28 14:39 :010_896300101703 :3/24/2005 3:27 PM :05/03/28 14:39 :010_896300101703 :3/24/2005 3:27 PM :05/03/28 14:39 :010_896300101703 :3/24/2005 3:27 PM :05/03/28
橡事例集表紙CD.PDF
Venture Project (A) (B) (C) (A) (B) (C) (A) (B) (C) (A) (B) (B) () 9:00 8:00 8:00 8:00 8:00 2 9:00 10:00 1 1) 10:00 ( 1 ) 15:00 12:00 14:00 ( ) ( ) 12:30 19:00 ( ) 16:30
[ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1
![[ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1](/thumbs/91/106630031.jpg "[ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1")
Simplify Sample Preparation [ SAMPLE PREPARATION SOLUTIONS ] [ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1 [ SAMPLE PREPARATION SOLUTIONS ] [ OASIS SAMPLE-EXTRACTION PRODUCTS ] 2 [ OASIS SAMPLE-EXTRACTION
LC/MS/MS によるフェノール類分析 日本ウォーターズ株式会社 2015 Waters Corporation 1 対象化合物 Cl HO HO HO フェノール 2- クロロフェノール (2-CPh) Cl 4-クロロフェノール (4-CPh) HO Cl HO Cl HO Cl Cl 2,4
LC/MS/MS による類分析 日本ウォーターズ株式会社 15 Waters Corporation 1 対象化合物 - クロロ (-CPh) 4-クロロ (4-CPh),4- ジクロロ (,4-DPh),6- ジクロロ (,6-DPh),4,6- トリクロロ (,4,6-TPh) 15 Waters Corporation 1 サンプル調製 ( 検量線 標準液 ) 5 標準溶液添加 (,,4,,,5uL)
DCR-PC300K/IPK
3-084-945-02(1) 6 19 31 34 39 2003 Sony Corporation * b 2 3 6 19 31 4 34 39 5 \ 6 * * * 7 1 2 * 3 b 4 1 2 5 6 8 7 1 8 1 2 *, 9 2 7 3 8 * 4 9 5 6 z 10 10 1 2 3 1 1 11 2 * 2, 11 3 8 4 5 9 6 7 12 13 b,,,,,
住まい・まちづくり活動事例集
3 H15 1982 1988 5 H16.31 1 1 1 246 26 3 2003 11 21,417/ 65 17.91% 16.62%1.29 246 2 1 12 1246 5008026 30080 3 200803 120060 2 20013 1 1 21 11 19821988 199112003 13 1988 1 1991 28 3 1991 1993 1992 1 1995
Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B
HPLC 3. µm BEH Stephan Koza, Susan Serpa, Hua Yang, Edouard Bouvier, and Kenneth J. Fountain Waters Corporation, Milford, MA, USA HPLC 200 0 HPLC 2 2010 UPLC 200 SEC 1 UPLC SE-UPLC 2 µm BEH BEH 100% SE-UPLC
MassPREP Mix %TFA 0.1% mg/ml < 70%DFVGYGVKDFVGVGVK 0.1%TFA 0.1% 1 4 mg/ml 1 ml/min UV 20 µl/min MS LC ACQUITY UPLC H-Class Bio
C 18 Matthew A. Lauber, Stephan M. Koza, and Kenneth J. Fountain Waters Corporation, Milford, MA, USA 2 BEH130 C 18 & 0.1%TFA c QC ACQUITY UPLC H-Class Bio XSelect 5 µm XBridge 5 µm MassPREP TM RP Charged
untitled
-1- -2- -3- AED -4- 2-5- -6- -7- -8-6-1-28 048-833-1231 2-1-1 048-261-3119 4389-1 048-556-3005 1-13-11 04-2924-1311 2097-1 048-738-3111 1172 04-2953-7111 990-1 048-565-1919 537 048-775-1311 2-2-2 048-924-2111
clover-375.pdf
8:4511:00 9:0012:30 9:0016:3003-5986-3188 AM PM AM PM AM PM AM PM AM PM AM PM - - - - - - 1 2 3 5 6 7 8:4515:00 9:0016:30 AM PM AM PM AM PM AM PM AM PM AM PM - - - - - - - - - () - - - - - - - 8 10 12
1
1 2 INDEX 3 4 5 6 7 8 60100150200 2 300 60 16 113 134 155 123 100 28 174 215 600 183 150 214 40 200 183 183 60 100 40 150 3 4 5 60 100 150 200 25 1150120 1150120 1150120 2640 1250120 1250120 1250120 200
untitled
ACQUITY UPLC SYNAPT TM G2 HDMS TM 130 2010/3/29 13:00-13:20 2010 Nihon Waters K.K. LC/MS Monoclonal Antibody Aspirin Insulin EPO MW 180 MW 6,000 MW 34,000 MW 147,000 2010 Nihon Waters K.K. 2 1 LC/MS ACQUITY
アプリケーションソフトウェアガイド PM2200C用
4013356-01 C01 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Printed
2016/17 P 1 P 8 P13 P18 P23 P28 7 P33 P41 15 P48 P65 GC-MS/MSLC-MS/MS 2016/17 2016 48 1.00 AH3 75.4% HI AH1pdm09 B AH3 D151GD151N HA AH1pdm09 AH3 B 5000 500 2016/17-1 - 2016 2017 78 24 well MDCKLLC-MK2HEp-2HeLa
筆王 for NEC
2 d 3 4 5 q w e r w e r q 6 q w q e 7 8 9 q q w w q w q w 10 11 12 q w 13 e q w e 14 q w q w e 15 r e 16 17 18 q w e 20 r q w t y q w e 21 u v v i o 22 !0!1!2 23 q w e 24 q w q w e e r y 25 q q w w q
JAJP.indd
Agilent VistaFlux 1 C- Hui Liu, Weige Qin, Hardik Shah, Bhavapriya Vaitheesvaran, Vladimir Yong, and Justin R. Cross Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering
Metabolomic Profiling_JA.qxp
LC/MS-TOF LC/Q-TOF GeneSpring MS BLB: Bacterial Leaf Blight Steven Fischer Senior Application Chemist Agilent Technologies Santa Clara, California U.S.A Theodore Sana Senior Research Scientist Agilent
*p145-174_Œâ‡í‡ê‡é
*p145-174_ 問 われる 09.1.16 10:34 PM ページ145 2007 200708 146 147 a s 148 a s d f g 153 a s d 158 a s d f g h j 166 a s d f 171 2009 145 *p145-174_ 問 われる 09.1.16 10:34 PM ページ146 45 2007 2008 146 *p145-174_
2 of 46 07.2.10 4:30 PM
1 of 46 07.2.10 4:30 PM 2 of 46 07.2.10 4:30 PM 3 of 46 07.2.10 4:30 PM 4 of 46 07.2.10 4:30 PM 5 of 46 07.2.10 4:30 PM 6 of 46 07.2.10 4:30 PM 7 of 46 07.2.10 4:30 PM 8 of 46 07.2.10 4:30 PM 9 of 46 07.2.10
JSF_No.100
J April 2006 JSF Today April 2006 No.100 J 1 2 9 11 14 15 17 18 20 21 24 26 31 1 J April 2006 1 2 JSF Today No.100 3 April 2006 4 JSF Today No.100 April 2006 5 6 JSF Today No.100 April 2006 7 8 JSF Today
2 7 ( ) µ 6 1873 6 6 6 2
140 2012 12 12 140 140 140 140 140 1 6 1873 6 6 6 2 3 4 6 6 19 10 39 5 140 7 262 24 6 50 140 7 13 =1880 8 40 9 108 31 7 1904 20 140 30 10 39 =1906 3 =1914 11 6 12 20 1945.3.10 16 1941 71 13 B29 10 14 14
薬物分析法の開発
API5000 TM LC/MS/MS Junichi_Hirokawa@trc.toray.co.jp 1. LC/MS/MS 2. 3. MS/MS 4. 5. API5000 6. 7. 8. 1. LC/MS/MS API 5000 AB/MDS Sciex UPLC API 4000 AB/MDS Sciex Agilent1100 PAL PAL ew wash 4000 QTRAP AB/MDS
untitled
HILIC ILIC BEH BEH 009 9 0 5 009 ihon Waters K.K. HILIC HILIC HILIC MS Sub-µm 009 ihon Waters K.K. HILIC? HILIC - Hydrophilic Interaction Chromatography 990 * HILIC (> 80%) *Alpert A. J. J.Chromatogr.
北アルプス_燕岳～穂高_－2.doc
1 ( )22 2001 2226 30 1300m 27kg 2 JR 1000 22 10 3 500-400 au 300 N 2763m 4 N N 10 N 500m PM9:00 5 ( 2 ) 7 23 2001 2226 10 N N 40 10 30 6 5m N N N 12 3 49 30 20 2922m 7 K ( ) U S N ( ) 50 15 N 35 (2758m)
『こみの株式会社』の実践
2003 . JA JA A JA 811 2005/8/11 1003 452 10 960 28 2005/8/11 1003 452 6 120 29 2005/8/11 2003 151 10 420 33 2005/8/11 2003 211 3 180 31 2005/8/11 2003 211 3 150 32 827 400 5 80 221 2005/6/25 900 3 300
15 7 26 1,276 3,800 1 16 15 1 2 3 4 2
1 15 7 26 1,276 3,800 1 16 15 1 2 3 4 2 JA 3 4 2 1 3 2001 1981 6 10% 10 30% 1 2 JA JA 2 4 JA 2 1 2 1 2 1 2 1 2 1 2 7 5 1 1 1 3 1 6 1 1 2 2 1 7 2 3 3 53 1 2000 30 8 250 53 435 20 35 3 1 8 2 4 3 2 2 232
EX-word_Library_JA
JA 2 3 4 5 14 7 1 2 6 3 1 2 7 3 8 27 1 2 3 1 2 3 9 1 2 3 1 2 3 10 12 13 14 11 1 12 1 2 13 1 2 3 25 14 1 2 3 25 15 1 2 3 25 16 1 2 3 25 17 1 2 3 25 18 1 2 3 4 25 19 1 2 3 4 25 20 1 2 21 3 4 25 22 1 2 3
324.pdf
50 50 10 30 11 26 12 27 14 16 27 18 20 21 22 22 22 22 23 24 24 1 No.324 JA 2 85 69 20 12 81 18 12 22 93 10 31 3 50 50 30 30 50 22 27 27 10 16 14 52 10 62 15 64 25 24 50 4 25 23 27 5 10 11 25 6 11 49 10
グローバリゼーションとイデオロギー（上）
187 57 1 IMF WTO 1 1 Abercrombie, Nicholas, and Bryan Turner, (1978) The Dominant Ideology Thesis, British Journal of Sociology, 29 (2), pp. 149-170. David McLellan, (1986) Ideology, Milton Keynes, UK:
1
1 1. 2 1-1. 2 3 1-2.2 4 2. 5 6 7 2-1 2-2 2-3 2-4 2-5 2-1 2-2 2-3 2-4 2-5 PDF PDF 8 P10 9 2-1. 10 2-1. 11 2-1. ( ( 12 2-1. 24 13 2-1. 3 3 14 2-1. 15 2-2. 16 17 2-2. 3 18 2-2. 19 2712 3 1000 20 2841 21 ...
low_ JAJP.qxd
LC/MS Chad Borges, Matthew Slawson, James Taccogno, and Dennis Crouch Center for uman Toxicology University of Utah Salt Lake City, UT USA John M. ughes Agilent Technologies, Inc. Pleasanton, CA USA (oa-tof)
mr0805.indd
62 MAY 2008 MAY 2008 63 64 MAY 2008 MAY 2008 65 66 MAY 2008 MAY 2008 67 68 MAY 2008 MAY 2008 69 70 MAY 2008 MAY 2008 71 72 MAY 2008 MAY 2008 73 74 MAY 2008 MAY 2008 75 76 MAY 2008 MAY 2008 77 78 MAY 2008
AC-2
AC-1 AC-2 AC-3 AC-4 AC-5 AC-6 AC-7 AC-8 AC-9 * * * AC-10 AC-11 AC-12 AC-13 AC-14 AC-15 AC-16 AC-17 AC-18 AC-19 AC-20 AC-21 AC-22 AC-23 AC-24 AC-25 AC-26 AC-27 AC-28 AC-29 AC-30 AC-31 AC-32 * * * * AC-33
エンジョイ北スポーツ
28 3 20 85132 http://www.kita-city-taikyo.or.jp 85 63 27 27 85132 http://www.kita-city-taikyo.or.jp 2 2 3 4 4 3 6 78 27, http://www.kita-city-taikyo.or.jp 85132 3 35 11 8 52 11 8 2 3 4 1 2 4 4 5 4 6 8
217/18 217 48 1. 2 AH1pdm9 AH3 B HI AH1pdm9 B AH3 D151GD151N HA 6 AH1pdm9 AH3 B 4 5 5 5 217/18-1 - 217 1 218 3 76 24 well MDCKLLC-MK2HEp-2HeLa RD-18sVero Caco-2 217/18 3 1).75% HI A(H1N1)pdm9 B 3 A(H3N2)
野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
1 No.236 HP TAXUS
Drug Information News 1 No.236 HP http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/236.pdf TAXUS 186 12 1 1 3050 L 30L 7L 1 (1 ) ( ) 510mm 2 1 2 ph 10 2030 瘙 瘙 瘙 瘙 瘙 瘙 瘙 瘙
() 1 1 2 2 3 2 3 308,000 308,000 308,000 199,200 253,000 308,000 77,100 115,200 211,000 308,000 211,200 62,200 185,000 308,000 154,000 308,000 2 () 308,000 308,000 253,000 308,000 77,100 211,000 308,000
1 2 http://www.japan-shop.jp/ 3 4 http://www.japan-shop.jp/ 5 6 http://www.japan-shop.jp/ 7 2,930mm 2,700 mm 2,950mm 2,930mm 2,950mm 2,700mm 2,930mm 2,950mm 2,700mm 8 http://www.japan-shop.jp/ 9 10 http://www.japan-shop.jp/
第18回海岸シンポジウム報告書
2011.6.25 2011.6.26 L1 2011.6.27 L2 2011.7.6 2011.12.7 2011.10-12 2011.9-10 2012.3.9 23 2012.4, 2013.8.30 2012.6.13 2013.9 2011.7-2011.12-2012.4 2011.12.27 2013.9 1m30 1 2 3 4 5 6 m 5.0m 2.0m -5.0m 1.0m
1 911 34/ 22 1012 2/ 20 69 3/ 22 69 1/ 22 69 3/ 22 69 1/ 22 68 3/ 22 68 1/ 3 8 D 0.0900.129mm 0.1300.179mm 0.1800.199mm 0.1000.139mm 0.1400.409mm 0.4101.199mm 0.0900.139mm 0.1400.269mm 0.2700.289mm